ONCOLYTICS BIOTECH INC (ONCY)

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring...

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

SAN DIEGO, CA and CALGARY, AB – December 18, 2024 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep’s potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American […]

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

/PRNewswire/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However,...

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/PRNewswire/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers...

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a...

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a...

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/PRNewswire/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to...

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/CNW/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on...

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84%...

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or […]

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/PRNewswire/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years....

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the...

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the...

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...